Cover Image
Market Research Report

Global Varicella Live Vaccine Market Forecast 2020-2028

Published by Inkwood Research Product code 923543
Published Content info 169 Pages
Delivery time: 2-3 business days
Price
Back to Top
Global Varicella Live Vaccine Market Forecast 2020-2028
Published: February 3, 2020 Content info: 169 Pages
Description

KEY FINDINGS:

The global varicella live vaccine market is estimated to grow and record a CAGR of 5.78% during the forecast period of 2020-2028. The factors fueling the market growth are the rise in the awareness of varicella live vaccine usage, a major boost in the acceptance of varicella vaccines, and active participation of government in immunization programs.

MARKET INSIGHTS:

The varicella live vaccines help to build immunity against the varicella-zoster virus, which can cause serious diseases like chickenpox and herpes zoster. Immunization with varicella live vaccines is an effective method to prevent these diseases. These vaccines are categorized mainly in two types, such as combination and monovalent.

One of the important factors propelling market growth is a boost in immunization programs across the globe. Active government initiatives and continuous efforts to ensure immunization boosts the varicella live vaccine market growth. In addition, there is a soaring increase in awareness regarding the usage of varicella vaccines in developing countries like India, owing to the presence of programs that discuss vaccines and vaccination. However, high monetary inputs associated with the production of the product hinders the growth of the market. There is intense competition in the market among Merck & Co. Inc., Sanofi, and Takeda Pharmaceutical Company Limited, which are the major shareholders in the market.

REGIONAL INSIGHTS:

The global varicella live vaccine market is geographically analyzed on the basis of the markets situated across the regions of North America, Europe, Asia Pacific, and the Rest of the World. As of 2019, the region of North America accounted for the largest market share in terms of revenue and continues the trend towards the end of the projected period. This is attributed to the easy availability of the varicella vaccines and the presence of the leading companies in the market, among other factors.The Asia Pacific region is predicted to register the highest growth rate in terms of revenue.One of the primary reasons is a surge in the availability of improved healthcare services.

COMPETITIVE INSIGHTS:

Merck & Co., Inc., Bio-Med Pvt. Limited, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, etc. are some of the principal companies operating in the market which have a global presence.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 29368

Table of Contents

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARIES

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. RISE IN THE AWARENESS OF VARICELLA LIVE VACCINES USAGE
    • 3.2.2. ACTIVE PARTICIPATION OF GOVERNMENT IN IMMUNIZATION PROGRAMS
    • 3.2.3. SURGE IN THE ACCEPTANCE OF VARICELLA LIVE VACCINES
  • 3.3. KEY RESTRAINTS
    • 3.3.1. TIME-CONSUMING PROCESS FOR THE DEVELOPMENT OF VARICELLA LIVE VACCINE
    • 3.3.2. HUGE CAPITAL EXPENDITURES
    • 3.3.3. SIDE EFFECTS ASSOCIATED WITH THE VARICELLA LIVE VACCINE

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. REGULATORY FRAMEWORK
    • 4.2.1. LEGAL REQUIREMENTS AND FRAMEWORK FOR VACCINES IN THE U.S.
    • 4.2.2. LEGAL REQUIREMENTS AND FRAMEWORK FOR VACCINES IN THE EUROPE
    • 4.2.3. LEGAL REQUIREMENTS AND FRAMEWORK FOR VACCINES IN THE ASIA-PACIFIC
  • 4.3. VARICELLA VACCINES ETYMOLOGY
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE

5. MARKET BY PRODUCT

  • 5.1. MONOVALENT VARICELLA VACCINE
  • 5.2. COMBINATION VARICELLA VACCINE

6. MARKET BY APPLICATION

  • 6.1. CHICKENPOX IMMUNIZATION
  • 6.2. HERPES ZOSTER IMMUNIZATION
  • 6.3. MMRV IMMUNIZATION

7. MARKET BY PROVIDER

  • 7.1. PRIVATE PROVIDER
  • 7.2. PUBLIC PROVIDER

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. THE UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. THE UNITED KINGDOM
    • 8.2.2. FRANCE
    • 8.2.3. GERMANY
    • 8.2.4. ITALY
    • 8.2.5. RUSSIA
    • 8.2.6. BELGIUM
    • 8.2.7. POLAND
    • 8.2.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. INDIA
    • 8.3.4. AUSTRALIA & NEW ZEALAND
    • 8.3.5. SOUTH KOREA
    • 8.3.6. THAILAND
    • 8.3.7. INDONESIA
    • 8.3.8. VIETNAM
    • 8.3.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST & AFRICA

9. COMPANY PROFILES

  • 9.1. BIO-MED PVT. LIMITED
  • 9.2. CHANGCHUN BCHT BIOTECHNOLOGY CO. LTD.
  • 9.3. GREEN CROSS HOLDINGS (GC PHARMA)
  • 9.4. EMCURE PHARMACEUTICALS LIMITED (ZUVENTUS HEALTHCARE LTD.)
  • 9.5. EMERGENT BIOSOLUTIONS INC.
  • 9.6. GLAXOSMITHKLINE PLC
  • 9.7. MERCK & CO. INC.
  • 9.8. MITSUBISHI CHEMICAL HOLDINGS CORPORATION (MITSUBISHI TANABE PHARMA CORPORATION)
  • 9.9. NOVAVAX INC.
  • 9.10. NOVO MEDI SCIENCES PVT. LTD.
  • 9.11. SANOFI
  • 9.12. TAKEDA PHARMACEUTICAL COMPANY LIMITED

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - VARICELLA LIVE VACCINE
  • TABLE 2: GLOBAL VARICELLA LIVE VACCINE, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL VARICELLA LIVE VACCINE, BY PRODUCT, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL VARICELLA LIVE VACCINE, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL VARICELLA LIVE VACCINE, BY APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL VARICELLA LIVE VACCINE, BY PROVIDER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL VARICELLA LIVE VACCINE, BY PROVIDER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL VARICELLA LIVE VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL VARICELLA LIVE VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: NORTH AMERICA VARICELLA LIVE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: NORTH AMERICA VARICELLA LIVE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: EUROPE VARICELLA LIVE VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: EUROPE VARICELLA LIVE VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: ASIA PACIFIC VARICELLA LIVE VACCINE, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: ASIA PACIFIC VARICELLA LIVE VACCINE, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: REST OF WORLD VARICELLA LIVE VACCINE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: REST OF WORLD VARICELLA LIVE VACCINE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: GLOBAL VARICELLA LIVE VACCINE, BY PRODUCT, IN 2019
  • FIGURE 5: GLOBAL VARICELLA LIVE VACCINE MARKET, BY MONOVALENT VARICELLA VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 6: GLOBAL VARICELLA LIVE VACCINE MARKET, BY COMBINATION VARICELLA VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL VARICELLA LIVE VACCINE, BY APPLICATION, IN 2019
  • FIGURE 8: GLOBAL VARICELLA LIVE VACCINE MARKET, BY CHICKENPOX IMMUNIZATION, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL VARICELLA LIVE VACCINE MARKET, BY HERPES ZOSTER IMMUNIZATION, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL VARICELLA LIVE VACCINE MARKET, BY MMRV IMMUNIZATION, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL VARICELLA LIVE VACCINE, BY PROVIDER, IN 2019
  • FIGURE 12: GLOBAL VARICELLA LIVE VACCINE MARKET, BY PRIVATE PROVIDER, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL VARICELLA LIVE VACCINE MARKET, BY PUBLIC PROVIDER, 2020-2028 (IN $ MILLION)
  • FIGURE 14: NORTH AMERICA VARICELLA LIVE VACCINE MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 15: THE UNITED STATES VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 16: CANADA VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 17: EUROPE VARICELLA LIVE VACCINE MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 18: THE UNITED KINGDOM VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 19: FRANCE VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 20: GERMANY VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 21: ITALY VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 22: RUSSIA VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 23: BELGIUM VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 24: POLAND VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 25: REST OF EUROPE VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 26: ASIA PACIFIC VARICELLA LIVE VACCINE MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 27: CHINA VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 28: JAPAN VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 29: INDIA VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 30: AUSTRALIA & NEW ZEALAND VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 31: SOUTH KOREA VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 32: THAILAND VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 33: INDONESIA VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 34: VIETNAM VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 35: REST OF ASIA PACIFIC VARICELLA LIVE VACCINE, 2020-2028 (IN $ MILLION)
  • FIGURE 36: REST OF WORLD VARICELLA LIVE VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 37: LATIN AMERICA VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 38: MIDDLE EAST & AFRICA VARICELLA LIVE VACCINE MARKET, 2020-2028 (IN $ MILLION)
Back to Top